Showing results (181-190 of 203) with videos related to

Sort By:
Pageof 21
ESMO Open|April 9, 2022
Safety and preliminary activity results of the GATTO study, a phase Ib study combining the anti-TA-MUC1 antibody gatipotuzumab with the anti-EGFR tomuzotuximab in patients with refractory solid tumorsS Ochsenreither, W M Fiedler, G D Conte, et al.
ESMO Open|April 25, 2025
Olaparib as a rescue treatment in platinum-refractory germ-cell tumors: the IGG-02 phase II trialG Schepisi, M Urbini, C Casadei, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 11, 2024
Pembrolizumab plus chemotherapy for advanced and recurrent cervical cancer: final analysis according to bevacizumab use in the randomized KEYNOTE-826 studyD Lorusso, N Colombo, C Dubot, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 2, 2024
ESGO-ESMO-ESP consensus conference recommendations on ovarian cancer: pathology and molecular biology and early, advanced and recurrent diseaseJ A Ledermann, X Matias-Guiu, F Amant, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 30, 2022
Efficacy of subsequent chemotherapy for patients with BRCA1/2-mutated recurrent epithelial ovarian cancer progressing on olaparib versus placebo maintenance: post-hoc analyses of the SOLO2/ENGOT Ov-21 trialJ S Frenel, J W Kim, N Aryal, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 3, 2019
Antitumor activity and safety of pembrolizumab in patients with advanced recurrent ovarian cancer: results from the phase II KEYNOTE-100 studyU A Matulonis, R Shapira-Frommer, A D Santin, et al.
European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology|March 27, 2018
Laparoscopic surgery in the treatment of stage I adult granulosa cells tumors of the ovary: Results from the MITO-9 studyA Bergamini, G Ferrandina, M Candiani, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 19, 2015
A randomized trial of intensive versus minimal surveillance of patients with resected Dukes B2-C colorectal carcinomaG Rosati, G Ambrosini, S Barni, et al.
ESMO Open|January 4, 2025
Unraveling the complexity of HRD assessment in ovarian cancer by combining genomic and functional approaches: translational analyses of MITO16-MaNGO-OV-2 trialB Pellegrino, E D Capoluongo, M Bagnoli, et al.
Gynecologic Oncology|September 15, 2019
Overall survival results of AGO-OVAR16: A phase 3 study of maintenance pazopanib versus placebo in women who have not progressed after first-line chemotherapy for advanced ovarian cancerI Vergote, A du Bois, A Floquet, et al.
Pageof 21